To determine whether loss of Dsc2 was accompanied by de novo expression of Dsc1 and Dsc3, we examined sporadic colorectal cancers (those previously analysed for Dsc2 expression by immunohistochemistry) using antibodies specific for Dscs 1 and 3. This evidence concerns the gene DSC2 and colorectal cancer.